中国医药(600056.SH)子公司达比加群酯胶囊获得药品注册证书

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. has received two drug registration certificates for Dabigatran Etexilate Capsules from the National Medical Products Administration [1] Group 1: Product Approval - Tianfang Pharmaceutical received approval for Dabigatran Etexilate Capsules in two specifications: 150mg and 110mg [1] - Dabigatran Etexilate is a direct thrombin inhibitor used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation [1] Group 2: Indications and Uses - The drug is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) [1] - It also helps lower the risk of recurrence of DVT and PE, and is used for the prevention of DVT and PE following hip replacement surgery [1]